Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How does this work exactly?
3 million sold, but only 700k bought?
Someone had to buy the other 2.3 million for them to be sold, right?
Curious to hear more about Redwood Management LLC.
In all my DD, I’ve never come across the company before. Albeit, I haven’t done recent DD on the company.
What’s the deal with them, what’s their affiliation, and why is it concerning?
Weak volume, reversal not confirmed.
Beware of a bull trap.
Close at $.025 means a green hammer on the weekly chart.
Going up from there.
“Canbiola is on the cusp of creating significant value for its shareholders...”
News out
“2.) insiders of the company are dilution experts - my opinion is they would be in the dilution hall of fame...”
I stopped reading this “Summary of ‘facts’” when I saw it was really just a bunch of opinions.
Just calling your opinions facts doesn’t make them such, and it certainly doesn’t make your opinion anymore convincing.
If they bought nearly 138,000,000 shares at $.029 ($4,000,000 investment), and those shares are now trading around $.021-.022, then yes they’ve lost value in the amount of almost $1,000,000.
I mean, am I missing something here?
Stock price goes does, monetary value goes down with it.
That is how it works, right?
Just a few weeks ago we saw CANB secure $4,000,000 in private placement at $.029/share...
As of right now, those shareholders are at a 27.5% loss, which means they’ve lost over $1,000,000 already.
There are a lot of bag holders here, but they have to be the biggest.
It’s concerning to see how this company trades, and even more concerning that CANB executives are running their investors into the ground.
Okay, “end of life situations” is a bit melodramatic.
Epidiolex isn’t some miracle drug that interrupts a life-threatening seizure. It’s used over a period of time in controlled doses to reduce the frequency of seizures occurring.
CBD is not going to be used by someone having a heart attack, or someone having a stroke, or someone who is in a real “end of life situation.” To say that any form of CBD is being used as such is ridiculous.
Furthermore, the term “medical grade” generally applies to medical devices. It simply means that a device is safe for use in a medical application, that the component is specifically designed to be used with, in, or on the human body, and the material is non-reactive to human tissue.
Pharmaceutical grade generally applies to drugs. Typically, a “pharmaceutical grade” drug is a drug that is at least 99% pure. That’s it. The terms simply denotes a degree of purity.
With that being said, if CANB CBD meets such standard for purity, it may very well be pharmaceutical grade CBD.
Again, you can be prescribed Tylenol by a physician, or you can go buy it from Walgreens, or you can go get it at a gas station.
Does the retail shelf it sits on make it any less acetaminophen?
My bad, I thought they were based out of Canada for some reason.
I stand corrected.
Yup, pretty serious... as a shareholder, why would I want CANB to charge less?
And as far as the medicinal value of isolate over full-spectrum is concerned, do you really think that a bunch of trained medical professionals would intentionally and knowingly prescribe a lesser treatment option when given the choice? Better yet, if the substance has “no beneficial value,” do you think they would be prescribing it to patients as a treatment option in the first place?
Have you heard of medical malpractice? You think all of these doctors are just out there engaging in malpractice, or what?
Do you seriously stand behind that claim?
“In America”
Reading is key... Charlotte’s Web is a Canadian company.
The concept of charging a premium price for medically prescribed substances is nothing new.
There are several factors that go into the prescription process that increase the price of the product (i.e., quality control measures, document control, insurance requirements, the doctor’s evaluation, etc.)
Why do you think a physician’s office will charge you several times more to prescribe a medication that can be had for a fraction of the price at a local drug store on your own?
Even then, you can walk into a local Walmart and find name brand Tylenol sitting next to a generic bottle of Acetaminophen for 2-3X’s the price.
Anyway, in the case of the prescription, the insurance provider covers a large majority of the cost, which usually leaves the patient with a small (even negligible) co-pay.
Which begs the question, if insurance providers are paying the premium price tag, who gives a damn?!
In fact, good on CANB for charging more where they can get more. I don’t see a problem with that at all.
If you bought the “going below $.01 hype” and sold out, you’ll probably be kicking yourself pretty soon.
The last two major runs followed immediately after hitting 52-week lows.
If you’ve heard of buying the bottom, this is it.
Buy now, average down now, do whatever you need to to get in right now. It’s going up from here.
I expect to see people selling off to recoup losses as it climbs, but as momentum increases we’ll see less and less selling.
“CANB has absolutely no reason to have an increase in shareprice. However, it has countless reasons for the shareprice to decrease.
Guranteed to go below .01”
Case in point...
Yes, this is the best time to buy, whether you are a bag holder or a newcomer.
The last two major runs were prefaced by a 52-week low.
We just hit a 52-week low.
If you are a newcomer, you can get in at basement bargain prices.
If you are a bag holder, you can substantially average down if you have funds available to do so.
Either way, it looks up from here.
This is probably the most relevant, factual piece of tangible information provided by anyone on this board in months.
There have been a lot of opinions, a lot of speculation, and a lot of useless banter back and forth about nothing.
These charts are an excellent illustration, and also explanation, for why CANB has been trending downward over the last couple of months.
In fact, this post, along with those links, should be pinned for all newcomers to see.
How does multiple revenue sources implicate an identity crisis?
Walmart sells groceries, clothes, camping items, tires, tools, etc.
Are they a tire shop, grocers, clothing retailers, a hardware store, or an outdoor store?
Hmm..
Your position on CBD isolate being a worthless product because it’s been “stripped down” and has “no beneficial ingredients” is patently false.
What you don’t realize is that the process of filtering out secondary and tertiary elements of a product, as to limit your end result to a primary ingredient, is used in all sorts of markets and with countless products. And in many cases, the isolated product is preferred.
For example, when you go to a supplement store to buy protein, you usually have some kind whey isolate, whey concentrate, or whey hydrolysate to choose from. They all come from the same source, but they’re processed differently.
By and large, whey isolate is the most common, most preferred, and most available form of whey protein. It’s clean, you know exactly what’s in it, and you can be sure you’re getting JUST protein.
With CBD, of it isn’t already, it will soon be very similar. People will want clean, pure CBD, and JUST CBD by itself.
That’s not to say that there won’t be a place for full-spectrum CBD, but there certainly will be a place for isolates.
Otherwise, there wouldn’t be such a big market for other isolated products like protein.
26% gain on 3,000 shares will not hold, don’t get too excited.
Honestly, if you have ANY doubts about CANB, do yourself a favor and look at the chart.
More specifically, compare the weekly chart from 2015 - current with the CVSI chart from 2015 - current.
CVSI’s epic run to $9.00+ started at $.10. By looking at the weekly chart you can see that the pattern formed a cup and handle over a 3-year period.
Once the base of the cup was formed, it only took 6 months to run over $9.00.
Now, look at CANB’s chart: almost the EXACT same thing happening.
We’re still rounding out the base now, but the second half of the cup is already forming.
Even if you don’t like a particular thing about CANB (I’ve been there before too), the chart is amazing.
This is ground-zero of another big runner.
Albeit the price looks dismal from here, the weekly chart is looking ready to explode.
Just last year, Canbiola ran from $.005 to $.06, and gave almost all of it back a few months later, dropping to $.01 (approximately double what the previous low was).
What’s notable about that 12-month period is that the chart experienced 3 peaks, all under a bear PSAR.
The fourth peak finally broke the PSAR and the price ran from $.01 to $.135 in a few weeks.
After that run, the chart has given almost all of back, but it’s also identically repeated itself.
Today the low reached $.022 (approximately double what the previous low was), and there have been 3 peaks under a bear PSAR since.
What’s more, the next peak (also the 4th in the last 12-month period) is close enough to the weekly PSAR that it’s almost guaranteed to be flipping in the next week or two.
All of that is to say that from a technical standpoint, barring some SMA crossovers and resistance, the next leg up looks like it’s very close.
Talk about shaking the tree!
If you haven’t gotten used to Canbiola’s drastic swings yet, this morning was probably a tough one to sit through.
Glad to see so many buyers picking up cheap shares today. If I had the extra funds, I’d be averaging down also.
Except.... they are...
I think he does a great job explaining in practical terms how Canbiola’s business model works.
They’re in hundreds of doctor’s offices, who each probably have hundreds of patients.
Weisberg explains that there is basically Tylenol or opioids for pain management, until CBD became available.
With that, Weisberg says he only gives ONE narcotic prescription to his patients, then it’s straight to CBD, and Canbiola CBD at that.
Hello! I like that approach to sales!
I can’t think of any other public CBD companies with the same approach to the market.
I’m not sure about the legal implications of a board member of a publicly traded company actively participating on a message board, but this video clears up Highlander’s accusations pretty well.
Albeit Weisberg is pretty long winded, he NEVER says he took a CANB PILL.
I hate it when I’m right..
This is EXACTLY what I was talking about. I was just explaining how these delays primarily kill trading momentum, and look at today’s open.
The first 20 minutes of trading after filing an extension and we’re only moving 3,000 shares? That’s $100.
This is beginning to feel like deja vu, CANB starts a strong trend upward and then does something that stops all progress.
It’s not a matter of being patient or impatient, it’s a matter concerning how the business of being run.
If you look at every quarterly report for the last 3 years, only TWO have been released on time.
The company may be ‘newer,’ but these guys have been in business long enough. CANB isn’t some brand new start up company, they’ve been around for a while now. If they were going to improve reporting times, they would have done it by now.
Realistically, sure, it’s not a big deal. But when they do things like this, especially ahead of highly anticipated results, it kills momentum and hurts investors.
I have my money in CANB and I do.
Primarily because habitually using the extensions is poor practice.
I realize there are no real consequences for utilizing the extension. It’s there for times when a company needs some extra time. If you need it, by all means, use it! But when you begin to rely on the extension as if it’s the actual deadline, and even miss the extended deadline, it suggests some greater internally systemic issue.
It boils down to one thing: competency. I want CANB firing on all cylinders, not 3 or 4.
Late again!
Jesus... can’t say I didn’t see that coming. I literally JUST explained how important it was for them to report ON TIME.
Because they extended today, they have 5 days, which means their new deadline is now Monday, August 19.
For the sake of each and every shareholder, they cannot miss that deadline. Every day they delay, you can be sure the share price will suffer.
Beyond all of this, CANB is shooting themselves in the foot with silly stuff like this. They make great progress in boosting investor confidence and then completely negate their efforts by make nonsensical moves like not reporting financials on time.
At this point, it’s not occasional - it’s habitual. Who wants to give their money to a group of unreliable people who can’t get the little things right?
I don’t mean to disparage the entire company by any means, but this is something that could have (and certainly should have) been fixed long ago.
I don’t mean to discourage your optimism or anything, but Canbiola has never reported on time, and they definitely don’t report early.
For the last several years, every financial report has come after an extension period, and sometimes even after the extension period has passed.
For quarterly reports, they are allowed to report 5 days from the day they request the extension (which can be requested the day after the report is due), so that means they could get a new due date of 8/20.
If they don’t make that deadline, we could be waiting much longer - who really knows?
The numbers are sure to be good, but what I don’t want to see is a lot of anticipation building up to the 15th, then an extension come out on the 16th, and then the trading momentum to crash as we wait several more days for the report to come out.
It does seem like CANB has done a better job in updating the market and shareholders about what they’re doing, and they’ve been providing a steady flow of PR’s recently. Now we’ll see if that change carries over to their reporting habits as well.
They’ve been notoriously late for several financial reporting deadlines, and even missed extension deadlines before.
We all know what happens when the market gets tired of waiting for financials to come out, and I don’t think that CANB’s PPS can handle another wave of doubt.
For the sake of shareholder confidence, share price, and shareholder value, they absolutely MUST report on time.
An on time report would really demonstrate a marked change in the way they’re running the business, and would likewise translate into increased shareholder/market confidence, and most likely an increase in share price.
But, time will tell..
A lot of people keep pointing out that CANB continues to be down after releasing a positive PR.
After following CANB for over year, I think those people fail to realize that CANB is churning through a pretty strong bear trend at the moment - along with almost every other cannabis/CBD company.
If you look back at posts from 12-18 months ago, many people complained about CANB not releasing enough PR’s. Now they are, and it’s all good news, but they happen to be stuck in a bear trend. If the overall trend is bear, PR’s are going to be enough to cause a reversal.
The fact of the matter is that market makers and traders can easily influence the share price, and the current trend is downward. For example, an order for just $10,000 at this price can easily induce panic buying or panic selling. Unfortunately, there isn’t much that longs can do to change that, other than to keep holding.
Nonetheless, CANB is making an obvious effort to release more information, and releasing it more frequently, and eventually the bear trend will reverse. When the trend reverses, and if CANB continues updating shareholders, we should see just the opposite effect when PR’s are released. Every release should bring big green gains.
More importantly, the long-term trend continues to be upward. The nature of a cup and handle formation requires big advancements coupled with small retracements. As of today, the cup hasn’t failed, so longs are still relatively safe.
I’m not personally thrilled about the last 30 days of price movement, but I am reasonable enough to understand that it is only a temporary condition. Every chart breakdown shows the current price action as being oversold, yet the company continues to improve fundamentally. This combination creates a textbook buying condition. That means that eventually longs will be rewarded.
On the other hand, I think that there are many longs underwater at this point (including myself), and that any substantial gain will be met with substantial selling. I’m concerned that the next major leg upward will be compromised by longs trying to recoup their loses at the first opportunity.
In the end, time will tell. I’ve gone from hawking CANB every hour to only checking a few times a week. I think that there is some decent looking long-term potential here, but it’s proven to be a tough ride for the near-sighted investor who is looking for a miracle. We’ll see what shakes out this fall.
I’ll try averaging down this week, and maybe even next week, which will put me around 1MM shares, but after that I think I’ll just be at the mercy of the market.
Good luck to everyone else.
Unfortunately, until we see some technical reversal, no PR is going to reverse this bear trend.
I’ll have to average down this week also.
“Falling knife” is a term often wrongly used to describe what’s actually oversold conditions.
For simplicity, I like to use the RSI to gauge overbought/oversold conditions. Anything below 30-35 can be considered oversold.
Over the last 12 months, every major uptick in share price (where it has at least doubled, tripled, or 10X’d) has been prefaced by the RSI indicating oversold conditions.
Today, the daily chart shows the RSI is at 34 - otherwise, oversold.
If that’s the case, I gladly welcome these conditions because I know what has followed historically.